AI-designed drug to enter human clinical trials for the first time

British start-up Exscientia and Japanese pharmaceutical firm Sumitomo Dainippon Pharma have created a drug molecule to treat Obsessive compulsive disorder using Artificial Intelligence.  The precisely engineered drug will enter phase one trials in Japan which, if successful, will be followed by more global tests. The firm is working on potential drugs for the treatment of cancer and cardiovascular disease and hopes to have another molecule ready for clinical trials by the end of the year. AI took 12 months to develop the drug molecule, which conventionally takes more than five years. The chief executive Prof Andrew Hopkins, Exscienta, described it as a “key milestone in drug discovery”..

Source – BBC news

Leave a Reply

Your email address will not be published. Required fields are marked *